Barclays Lowers Boston Scientific (NYSE:BSX) Price Target to $100.00

Boston Scientific (NYSE:BSX) had its price target cut by investment analysts at Barclays from $124.00 to $100.00 in a research note issued on Wednesday, MarketBeat Ratings reports. The firm currently has an “overweight” rating on the medical equipment provider’s stock. Barclays‘s price target would suggest a potential upside of 51.76% from the stock’s current price.

A number of other equities research analysts have also issued reports on BSX. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $112.00 target price on shares of Boston Scientific in a report on Friday, February 6th. Canaccord Genuity Group dropped their target price on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Boston Scientific in a report on Monday, March 16th. Argus raised shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Finally, TD Cowen dropped their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a report on Monday, February 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average price target of $93.91.

Boston Scientific Stock Performance

NYSE:BSX opened at $65.89 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The company has a fifty day moving average of $68.71 and a two-hundred day moving average of $86.02. The stock has a market capitalization of $97.93 billion, a PE ratio of 27.57, a P/E/G ratio of 1.03 and a beta of 0.78. Boston Scientific has a fifty-two week low of $59.38 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the prior year, the business posted $0.75 earnings per share. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts forecast that Boston Scientific will post 3.36 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares during the period. State Street Corp grew its holdings in shares of Boston Scientific by 1.4% in the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares during the period. Capital World Investors grew its holdings in shares of Boston Scientific by 1.9% in the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares during the period. Norges Bank purchased a new stake in shares of Boston Scientific in the fourth quarter valued at about $2,199,395,000. Finally, Morgan Stanley grew its holdings in shares of Boston Scientific by 10.8% in the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after purchasing an additional 2,246,308 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results beat estimates: Boston Scientific reported $5.20B in sales (up ~11.6%) and adjusted EPS of $0.80, topping consensus and showing broad demand across key cardiovascular franchises. This underpins the bullish view on organic growth drivers. Boston Scientific announces results for first quarter 2026
• Positive Sentiment: Market reaction / reset thesis: Some analysts and outlets framed the guidance cut as a constructive “reset” that creates a buying opportunity if management executes on long-term initiatives; that framing helped shares recover after the release. Boston Scientific Just Slashed Guidance and Wall Street Followed. Is the Pullback a Buying Opportunity?
• Neutral Sentiment: Analysts cut targets but largely kept bullish ratings: Multiple firms trimmed price targets (Truist, Baird, Needham, Jefferies, Barclays) while maintaining buy/outperform calls — signaling shorter-term caution but continuing confidence in longer-term upside. Boston Scientific Analysts Slash Their Forecasts After Q1 Earnings
• Neutral Sentiment: Broker commentary called the guidance cut “prudent” with a Q2 trough expected; analysts are modeling a weaker near term but still see recovery later in 2026. That supports mixed near-term sentiment but keeps longer-term forecasts intact. Boston Scientific 2026 Guidance Cut ‘Prudent,’ Q2 Trough Expected, RBC Says
• Negative Sentiment: Guidance cut: Management trimmed FY2026 EPS and revenue guidance below Street consensus and signaled softer near-term procedure volumes in some product lines — the primary reason for the re-rating and analyst target cuts. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Legal risk and class-action notices: Multiple law firms have announced investigations and class-action filings alleging misstatements around procedure demand and disclosures; this raises potential litigation costs and short-to-medium-term headline risk. BOSTON SCIENTIFIC ALERT: Bragar Eagel & Squire, P.C. is Investigating Boston Scientific Corporation

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.